• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Diseases & Conditions

  • All Diseases and Conditions

The following clinical trials are associated with All diseases and conditions.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next
  • expand Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms
    Study Id
    D589LL00001
    Disease
    asthma
    Drug Name
    Symbicort Turbuhaler
    Study Name
    D589LL00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Symbicort Turbulaler 30/60 Special Clinical Experince Investigation for long-term use for COPD patients
    Study Id
    D589DL00001
    Disease
    chronic obstructive pulmonary disease
    Drug Name
    Symbicort Turbuhaler
    Study Name
    D589DL00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV).
    Study Id
    D1532C00064
    Disease
    non-small cell lung cancer
    Drug Name
    AZD6244
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)
    Study Id
    NIS-CIN-XXX-2011/3
    Disease
    diabetes mellitus, diabetes type 2
    Drug Name
    Onglyza
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada
    Study Id
    D4200L00059
    Disease
    thyroid cancer
    Drug Name
    Caprelsa
    Study Name
    D4200L00059
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
    Study Id
    D5135C00001
    Disease
    myocardial infarction
    Drug Name
    Brilinta
    Study Name
    D5135C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma
    Study Id
    D3551C00001
    Disease
    asthma
    Drug Name
    AZD5069
    Study Name
    D3551C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Retrospective Cohort Study on Therapeutic Management of Metastatic Breast Cancer in Clinical Practice in Bulgaria
    Study Id
    NIS-OBG-XXX-2012/1
    Disease
    breast cancer
    Drug Name
    non drug study (oncology)
    Study Name
    NIS-OBG-XXX-2012/1
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
    Study Id
    D4200C00098
    Disease
    thyroid cancer
    Drug Name
    AstraZeneca Oncology and Infection Brands
    Study Name
    D4200C00098
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety, Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (PYRUS)
    Study Id
    D3610C00003
    Disease
    prostate cancer
    Drug Name
    AstraZeneca Oncology and Infection Development Drugs
    Study Name
    PYRUS
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013